Investigates semaglutide's impact on biological markers in early Alzheimer's disease, suggesting potential therapeutic effects.
To investigate the effects of semaglutide on transcriptomics, proteomics and biomarkers in patients with early Alzheimer’s disease (AD).
No takes yet. Share an insight, caveat, or question.
Frederiksen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: